戻る Agenda
Session 9: Considerations for Medication Error Pharmacovigilance
Session Chair(s)
Jo Wyeth, PharmD
Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
FDA, United States
Medication errors have a significant public health burden. This session will discuss the impact of medication errors, current state of medication error pharmacovigilance, and propose directions for building a pharmacovigilance medication error program for the future.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Recognize that medication error prevention requires a collaborative effort among regulators, industry, patients, healthcare providers, and other stakeholders
- Identify differences and challenges in the approach for medication error pharmacovigilance versus adverse event pharmacovigilance
- Describe current and emerging approaches for surveilling medication errors
Speaker(s)
Medication Errors: Impact on the Victims
Christina Michalek, RPh
Institute for Safe Medication Practices , United States
Medication Safety Specialist
Speaker
Reema Mehta, PharmD, MPH
Pfizer Inc, United States
Senior Director, Head of Risk Management and Safety Surveillance Research
Roadmap for Medication Error Pharmacovigilance
Jo Wyeth, PharmD
FDA, United States
Associate Director for Postmarket Assessments, OMEPRM, OSE, CDER
Natural Language Processing and Machine Learning with Patient Safety Event Reports
Allan Fong, MS
Medstar Health National Center For Human Factors In Healthcare, United States
Research Scientist and Data Scientist
Panelist
Lubna Merchant, PharmD, MS
Pfizer Inc , United States
Director, Risk Management Center of Excellence